Australia's IonOpticks responds to growing global market needs for proteomics tools by partnering with Nordic private equity firm

Australia-based IonOpticks, a leading global producer of high-performance chromatography columns, has announced its partnership with Adelis Equity Partners. The Nordic private equity firm is renowned for partnering with and accelerating the growth of companies in their focus sectors including healthcare and life sciences.

The investment from Adelis will augment IonOpticks' global presence and drive innovation as the company expands closer to key markets and consolidates its leading position in the exciting and rapidly growing field of proteomics and adjacent applications.

The strategic partnership will enable IonOpticks to scale its operations globally, enhancing product development and better positioning the company to serve its growing customer base. Being closer to its customers and collaborators while also ensuring compatibility across major LC-MS platforms is a key priority, allowing researchers worldwide to benefit from IonOpticks' class-leading chromatography.

Adelis' extensive experience, industrial advisor network and resources will support IonOpticks in maintaining its position as the provider of the best solutions for LC-MS proteomics research.

IonOpticks produces high-performance chromatography solutions for the global research community enhancing mass spectrometry (LC-MS) and high-end proteomics research. Their solutions enhance the sensitivity of mass spectrometry sample analysis, enabling scientists and clinicians to discover more from their samples. These advancements are valuable for a broad range of applications within the field of biological and medical research including drug discovery, phosphoproteomics and shotgun proteomics.